CD274 and non-small cell lung carcinoma: This suggests that the combination of chidamide and envafolimab may have potential clinical efficacy in some anti‐PD‐1 resistant NSCLC patients, but further identification of this population (particularly negative PD‐L1/low‐level TMB/cold tumors) is needed.